Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
July 29, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the "Company") received a notification from the National Medical Products Administration (the "NMPA") regarding the approval of the market launch of insulin sudelidec injection, a Class 1 therapeutic biological product independently developed by the Company. This product is China's first independently developed long-acting insulin analog. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Drug name: Insulin sudelidec injection

Dosage form: Injection

Strength: 3 mL: 300 units (pre-filled pen injector), 3 mL: 300 units (cartridge)

Registration category: Class 1 therapeutic biological product

Acceptance No.: CXSS2500010, CXSS2500011

Prescription/over-the-counter drug: Prescription drug

Approved indication: For the treatment of adults with type 2 diabetes mellitus (T2DM).

II. Other Information of the Drug

Diabetes mellitus is a metabolic syndrome characterized by hyperglycemia

resulting from defective insulin secretion and/or insufficient insulin action. China has the world's largest diabetes patient population, with the number reaching 148 million[1], among which patients with T2DM experiencing a progressive decline in islet function account for over 90% of total diabetes cases[2]. Insulin plays an important role in the treatment of diabetes, but hypoglycemia (especially nocturnal hypoglycemia) remains a major obstacle for some patients in achieving stable blood glucose control and long-term standardized treatment.

Insulin sudelidec injection, a long-acting basal insulin independently developed by the Company, offers a smooth and stable onset of action, long duration of effect, and low risk of nocturnal hypoglycemia. This approval is mainly based on two pivotal Phase III clinical trials of insulin sudelidec (development code: INS068) in adult patients with T2DM: Study INS068-301 and Study INS068-302 [3,4]. The results showed: for Chinese patients with T2DM in two different treatment settings (inadequate glycemic control with basal insulin or oral antidiabetic agents), insulin sudelidec demonstrated overall comparable efficacy to insulin glargine in glycemic control [3,4], with a lower risk of nocturnal hypoglycemia than insulin glargine.

Currently, similar products have been approved for launching worldwide, such as Novo Nordisk's insulin degludec (Tresiba®) and Sanofi's insulin glargine (Toujeo®). According to the EvaluatePharma database, the combined global sales of Tresiba® and Toujeo® in 2025 were approximately US$3.345 billion. As of now, the cumulative R&D investment in insulin sudelidec injection-related projects is approximately RMB 544.30 million (unaudited).

III. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

July 29, 2026

1. IDF Diabetes Atlas 11th edition.
2. Chinese Diabetes Society, Chinese Medical Association. Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2024 Edition). Chinese Journal of Diabetes Mellitus. 2025;17(1):16-139.
3. Hong Chen, et al. Efficacy and safety of a once-daily basal insulin (insulin sudelidec) vs insulin glargine in type 2 diabetes inadequately controlled with basal insulin. ePoster presented at EASD 2025. POSTER ID ePID2025.
4. Leili Gao, et al. Efficacy and safety of a once-daily basal insulin (insulin sudelidec) vs insulin glargine in type 2 diabetes inadequately controlled with oral antidiabetic drugs. ePoster presented at EASD2025. POSTER ID ePID1944.